Reversal Agents

Managing Reversal Of Direct Oral Anticoagulants In Emergency Situations

A Prospective Cohort Study Of Idarucizumab For Reversal

Idarucizumab: The Antidote For Reversal Of Dabigatran

Videos Dabigatran Reversal Andexanet Alfa Ciraparantag Guidelines

Reversal Agents - New This Month

Specific antidotes for bleeding associated with direct oral anticoagulants

Burnett A, Siegal D, Crowther M, et al

BMJ 2017;357:j2216
Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management

Alexander Niessner, Juan Tamargo Menendez, João Morais, et al

Eur Heart J (2017) 38 (22): 1710-1716.
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

Charles V. Pollack, Paul A. Reilly, Joanne van Ryn, et al

Reversal Agents - Idarucizumab for Dabigatran Reversal

Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial

Stephan Glund, J. Stangier, Michael Schmohl, et al

Lancet 2015; 386: 680–690.
A Prospective Cohort Study of Idarucizumab for Reversal of Dabigatran-Associated Hemorrhage

Robert M. Starke, Ricardo J Komotar, E. Sander Connolly, et al

Neurosurgery. 2015 Dec;77(6):N11-3.
Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects

Paul A. Reilly, J. van Ryn, Oliver Grottke, et al

Am J Med. 2016 Nov;129(11S):S64-S72.
Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases

Milan R. Vosko, Christof Bocksrucker, Rafał Drwiła, et al

J Thromb Thrombolysis. 2017 Apr;43(3):306-317.

Reversal Agents - Andexanet Alfa for Factor Xa Inhibitors

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy Subjects By Andexanet Alfa (PRT064445), An Antidote For Fxa Inhibitors

Mark Crowther, Mathur Vandana, Kitt Michael, et al

Blood 2013 122:3636;
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal of Edoxaban-Induced Anticoagulation in Healthy Subjects By Andexanet Alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors

Mark Crowther, Gallia G. Levy, Genmin Lu, et al

Blood 2014 124:4269;
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors

Stuart J. Connolly, Truman J. Milling, John Eikelboom, et al

N Engl J Med. 2016 Sep 22;375(12):1131-41.

Reversal Agents - Ciraparantag for Factor Xa Inhibitors

Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin

Jack E. Ansell, Bryan E. Laulicht, Sasha H. Bakhru, et al

Thromb Res. 2016 Oct;146:113-118.
Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban

Jack E. Ansell, Sasha H. Bakhru, Bryan E. Laulicht, et al

Thromb Haemost. 2017 Jan 26;117(2):238-245.

Reversal Agents - Guidelines/expert recommendations

Reversal of Direct Oral Anticoagulants: Current Status and Future Directions

Jeffrey I. Weitz

Semin Respir Crit Care Med. 2017 Feb;38(1):40-50.
Managing reversal of direct oral anticoagulants in emergency situations

Walter Ageno, Harry R. Buller, A. Falanga, et al

Thromb Haemost. 2016 Nov 30;116(6):1003-1010.
When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH

Jerrold H. Levy, Walter Ageno, N. C. Chan, et al

J Thromb Haemost. 2016 Mar;14(3):623-7.
Management of Patients on Non–Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association

Amish N. Raval, Joaquin E. Cigarroa, Mina K. Chung, et al

Circulation. 2017;135:e604-e633

SPAF News

FDA Approves First Generic Naloxone Nasal Spray to Treat Opioid Overdose

20 April 2019

April 19, 2019 -- The U.S. Food and Drug Administration today granted final approval of the first...
Statins Safe, Effective in Rheumatoid Arthritis Patients

19 April 2019

FRIDAY, April 19, 2019 -- Daily atorvastatin is safe for the primary prevention of cardiovascular...
FDA Approves First Generic Nasal Spray Against Opioid Overdose

19 April 2019

FRIDAY, April 19, 2019 -- The first generic naloxone nasal spray to treat opioid overdose has...
Increased Screen Time in Preschool Tied to Worse Inattention

19 April 2019

FRIDAY, April 19, 2019 -- Increased screen time in preschool is associated with increased odds of...
Atrasentan Tied to Lower Risk for Kidney Events in T2DM With CKD

19 April 2019

FRIDAY, April 19, 2019 -- Atrasentan is associated with a reduced risk for renal events in patients...
Informational Film Improves Knowledge on Lung Cancer Screening

19 April 2019

FRIDAY, April 19, 2019 -- An informational film can improve knowledge and reduce decisional...